TY  - JOUR
AU  - Burtness, Barbara
AU  - Haddad, Robert
AU  - Dinis, Jose
AU  - Trigo, Jose
AU  - Yokota, Tomoya
AU  - de-Souza-Viana, Luciano
AU  - Romanov, Ilya
AU  - Vermorken, Jan
AU  - Bourhis, Jean
AU  - Tahara, Makoto
AU  - Martins-Segalla, Jose Getulio
AU  - Psyrri, Amanda
AU  - Vasilevskaya, Irina
AU  - Nangia, Chaitali Singh
AU  - Chaves-Conde, Manuel
AU  - Kiyota, Naomi
AU  - Homma, Akihiro
AU  - Holeckova, Petra
AU  - Del-Campo, Josep Maria
AU  - Asarawala, Nirav
AU  - Nicolau, Ulisses Ribaldo
AU  - Rauch, Daniel
AU  - Even, Caroline
AU  - Wang, Bushi
AU  - Gibson, Neil
AU  - Ehrnrooth, Eva
AU  - Harrington, Kevin
AU  - Cohen, Ezra E W
PY  - 2019
DO  - 10.1001/jamaoncol.2019.1146
UR  - http://hdl.handle.net/10668/14105
T2  - JAMA oncology
AB  - Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC. To assess...
LA  - en
PB  - American Medical Association
KW  - Carboplatin
KW  - Squamous Cell Carcinoma of Head and Neck
KW  - Disease-Free Survival
KW  - Hypopharynx
KW  - Neoplasm Recurrence, Local
KW  - Medical Futility
KW  - Random Allocation
KW  - Oropharynx
KW  - Chemoradiotherapy
KW  - Stomatitis
KW  - Epithelial Cells
TI  - Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
TY  - research article
VL  - 5
ER  -